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Abstract
Introduction: Angiogenesis is a normal physiological process that plays an imperative 
role during tumor development. We believe that the development of a non-invasive imag-
ing technique targeting angiogenesis can provide a better understanding of this important 
process. Positron emission tomography (PET) – a highly sensitive imaging technique can 
offer accurate degree of disease quantification. The phenomenon of enhanced permeabil-
ity and retention effect (EPR effect) is now becoming the gold standard in cancer targeting 
drug designing. Dendrimers have the ability to exhibit EPR effect for targeted therapeu-
tic/drug delivery approach. Therefore, molecular imaging of tumor angiogenesis using 
radio-labeled dendrimers is expected to broaden the possibilities for drug development.
Body: In the present chapter, the significance of performing conjugation chemistry of 
bifunctional chelators quality control parameters of the radiolabeled dendrimer conju-
gates in vitro stability, animal biodistribution, radiation dosimetry and molecular imag-
ing of animal tumor model after injecting radiotracer have also been discussed in detail.
Conclusion: Conjugation of the radio-metal complexes to larger molecules like den-
drimers has created a new domain of research in the field of biomedical applications. 
Therefore, it has been proposed to develop new effective targeting moieties suitable for 
radiolabeling with PET tracers so as to perform molecular imaging studies.
Keywords: dendrimers, radiolabeling, PET imaging, tumor angiogenesis
1. Introduction
The present chapter highlights the importance of dendrimer based radio imaging of angiogen-
esis as a novel approach for molecular imaging of carcinogenesis because of their topology, 
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functionality and dimensions. The high loading capacity of dendrimers enables them to deliver 
chemotherapeutic agents as well. The dendrimer-drug complexes designed for either targeted 
or non-targeted drug delivery successfully penetrate through the leaky vasculature of tumor 
and accumulate in the cancer tissue. However, the added advantage of using dendrimer-drug 
complexes specifically designed for targeted delivery is that they bind to specific receptors over-
expressed on the surface of cancer cells, thereby, increasing their residence time over the cell 
surface. Thus, the development of dendrimer complexes that incorporate the targeting ligands, 
anticancer drugs and positron emission tomography (PET)/β emitting radionuclides may pro-
vide the way for combinational anticancer therapies along with the in vivo imaging of the tar-
geted tumor.
2. Tumor angiogenesis
Angiogenesis is an essential physiological process that involves formation of new blood ves-
sels from the pre-existing ones and is one of the fundamental processes required for normal 
growth and development [1]. It has been recognized long ago that most solid tumors are per-
fused by large number of blood vessels [2]. The ability of a tumor to stimulate the formation 
of new blood vessels enables expansion of tumors, local invasion and dissemination. Thus, 
angiogenesis is also considered as one of the key requirements during tumor development 
as it provides oxygen and nutrients to the otherwise dormant tumors and without which the 
tumor cannot grow beyond 2.0–3.0 mm in diameter [3, 4]. Tumor comprises of cells that pro-
liferate aberrantly and have lost the ability to regulate growth. Thus, tumor cells like normal 
cells require adequate supply of oxygen and nutrients and also needs an effective mean to 
remove wastes in order for metabolic processes to occur [5]. In order to fulfill these require-
ments, tumor cells can establish their own blood supply and this ability of tumors to promote 
the formation of new capillaries from the pre-existing ones is called the angiogenic switch. 
Tumor induced blood vessels are abnormal and leaky in nature. Since, the leaky vasculature 
of tumor blood vessels provides an efficient route of exit for tumor cells to leave the primary 
site and enter the main circulation, angiogenesis, thus has been considered as the critical com-
ponent of metastasis [6].
3. Imaging of tumor angiogenesis
Angiogenesis is considered as an important therapeutic target in both cardiovascular and 
malignant diseases [7]. In cardiovascular diseases, the therapeutic goal is to perfuse the isch-
emic tissue and to promote recovery from ischemic injury by inducing angiogenesis [8, 9]. 
On the other hand, in tumor angiogenesis, the angiogenic therapeutic approach is based on 
inhibiting angiogenesis, which is responsible for tumor growth and metastasis [10]. This fact 
has led to an increased search for new anti-angiogenic molecules and to design targeted anti-
angiogenic strategies for cancer treatment and the prevention of cancer recurrence or metasta-
sis [11, 12]. Further, with the increasing use of anti-angiogenic drugs in the field of oncology, 
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the importance of imaging the angiogenic process has also increased. Various candidates 
for diagnosing angiogenesis include vascular endothelial growth factor (VEGF), circulating 
endothelial progenitor cells and biopsy specimens.
Though, biopsy specimens are extremely rich in information but they suffer a limitation from 
sampling bias and inherent invasiveness. The traditional gold standard measure of angiogen-
esis is the histological estimate of microvascular density (MVD) which quantifies the average 
number of micro vessels within a selected microscopic field. However, this method is invasive 
and will vary according to the location from which the biopsy is taken and may cause under 
or overestimation of the degree of angiogenesis.
Thus, the development of non-invasive imaging technique, specifically targeting angiogen-
esis among other biological processes would provide a better understanding of this important 
process and would also enable the evaluation of anti-angiogenic effect of new drugs adminis-
tered as adjuvant therapy to reduce tumor growth.
4. Imaging techniques
Certain imaging modalities like computed tomography (CT) angiography, high resolution 
magnetic resonance angiography and contrast enhanced ultrasound are available for struc-
tural visualization of microvasculature. Multi detector (MDCT) angiography has better 
spatial and temporal resolution and is considered as the most useful modality in evaluat-
ing vascular structures [13]. The spatial resolution of MDCT is about 1.0 mm and the size 
of a human capillary is about 7.0–10.0 μm. Thus, MDCT can still not adequately visual-
ize microvasculature [14]. Several molecules like growth factor receptors, tyrosine kinase 
receptors and G-protein coupled receptors can be used as specific targets for angiogenesis 
imaging [7].
Radionuclide based imaging techniques like single photon emission computed tomography 
(SPECT) and PET can offer accurate degree of disease quantification (progression/regression) 
in view of the high sensitivity of these imaging modalities [15]. In PET imaging, the annihila-
tion of an electron-positron pair gives rise to two 511 KeV gamma ray photons being emitted 
at 180°. These high energy photons are then detected by a detector ring which is made up of 
crystals like bismuth germanium oxide (BGO), gadolinium oxyorthosilicate (GSO) or lute-
tium oxyorthosilicate (LSO).
Undoubtedly, the success of such this modality lies with the development of specific molecu-
lar imaging probes for the accurate diagnosis of angiogenesis and for identifying the respond-
ers/non-responders at an early stage after the initiation of treatment [7]. Over the last decade, 
PET imaging has emerged as a very powerful imaging technique for use in the direct imaging 
of angiogenesis in animal (eventually human) models, an early diagnosis, complete staging 
and early treatment response assessment [16]. The ability of PET imaging to detect picomolar 
concentration of tracer accumulation makes it several times more sensitive technique than 
the SPECT imaging [17]. PET imaging not only enables in vivo visualization of physiological 
processes at molecular level but also helps in its quantification. PET may be considered as a 
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functional or a targeted imaging modality. The staging can be done more accurately using 
PET when compared to any other conventional diagnostic means and thus it might be used 
independently as the first diagnostic choice [18].
5. Role of dendrimers in angiogenesis imaging
Most of the low molecular weight anticancer drugs have a characteristic to move in and 
out of blood vessels freely, unless the drug is linked with a tumor specific molecular ligand 
like anti-VEGF antibodies or receptor-specific ligands having high binding constant [19]. 
However, despite their high selectivity, the slow clearance rate of antibodies limits their 
clinical application. Recent studies have revealed that tumor cells have diverse epitopes 
because of great magnitude of mutation frequency even among the same cancer patient. 
Thus, the specific antibodies and ligands show inefficient binding with each of the diverse 
epitopic targets [20, 21]. In order to overcome this problem, the phenomenon of enhanced 
permeability and retention effect (EPR effect) is now becoming the gold standard in can-
cer targeting drug designing. The EPR effect is based on macromolecular, polymeric and 
micellar particles including nanoparticles [22]. The leaky blood vessels of tumors enables 
the molecules of size greater than 40 kDa to escape out of the tumor blood vessels and accu-
mulate into the tumor tissues whereas this EPR effect is not present in normal tissues [23]. 
Thus, this unique phenomenon of EPR effect is being exploited increasingly for anticancer 
drug development.
The concept of nanomedicine has been used extensively to develop biocompatible products 
for targeted drug delivery and sustained drug release at the targeted sites [24]. Nanomedicine 
is an emerging field that deals with interactions between molecules, cells and engineered 
substances like molecular fragments, atoms and molecules They have a high available surface 
area per unit of volume and they can be engineered to have different sizes, shapes and chemi-
cal compositions, hollow or solid structures [25]. Nanodelivery systems are believed to allow 
for more specific targeting. Nanotechnology products like fullerenes or dendrimers, macro-
molecular, micellar and polymeric particles have the ability to exhibit EPR effect for targeted 
therapeutic/drug delivery approach [22, 24].
Dendrimers are highly branched; 3-dimensional polymeric structures which are usually clas-
sified by the number of repeated branching cycles formed during synthesis and are reported 
to have an emerging role in a variety of biomedical applications [26]. They can be used as bio-
mimetic catalysts, drug carriers, gene delivery and can also be used in boron neutron capture 
therapy [27–30]. The dendrimers are considered potentially advantageous due to their numer-
ous surface functional groups, relatively low immunogenicity and also their size, which is 
very close to various important biological polymers. Lower generation dendrimers are asym-
metric in nature and are considered as more open structures when compared to dendrimers 
of higher generation. With the increasing generation, dendrimers acquire a globular structure 
[31] and forms a closed membrane like structure due to the dense packing of branches.
Dendrimers are monodisperse molecules and their solubility is influenced by the nature of 
functional groups present on the surface of dendrimers, that is, dendrimers with hydrophilic 
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terminal groups are soluble in polar solvents whereas dendrimers possessing hydrophobic 
end groups are soluble in non-polar solvents [32]. The need to study the biological properties 
of dendrimers is very important because of their increasing use in biomedical applications. 
The molecular dimensions of dendrimers are comparable to medium sized proteins [33].
Though, dendrimers have been extensively used as magnetic resonance imaging (MRI) 
contrast agents and drug delivery carriers, however, the complex of radionuclides with 
polyamidoamine (PAMAM) dendrimers in order to perform molecular imaging of tumor 
angiogenesis is a new field. In the past, dendrimers have been extensively studied as pro-
spective carriers for drug delivery, gene delivery and moieties for modifying the drug solu-
bility and absorption [34, 35]. The geometry of the molecule and the charges present on 
the surface of dendrimers influence the microvascular extravasation of polymers across the 
endothelial barrier.
EPR effect has been widely used for passive targeting of macromolecular anticancer agents to 
angiogenic solid tumors. Dendrimers with hydrophilic surfaces and molecular weights above 
25–30 kDa are usually retained in the circulation for longer periods and provide an enhanced 
opportunity for passive targeting via EPR effect.
Many studies describing the process of dendrimer-chelator conjugation and subsequent 
complexation with metal ions and the potential use of dendrimers as probes in MRI and 
fluorescent imaging have been cited previously [36, 37]. However, studies with regard to 
radiolabeling of these dendrimer-chelator conjugates as PET imaging probes are very few.
6. Radionuclides used for molecular imaging of dendrimers
More than 80.0% of the radiopharmaceuticals used in nuclear medicine imaging are techne-
tium −99 m (99mTc) based tracers. However, a dramatic shift toward the development of PET-
based novel tracers using fluorine-18 (18F), carbon-11 (11C), gallium-68 (68Ga) and copper 64 
(64Cu) positron emitters have been witnessed over the last few years. Majority of these radio-
pharmaceuticals are administered intravenously. Radiopharmaceuticals can be divided into 
diagnostics and therapeutics depending on their medical applications. Diagnostic radiophar-
maceuticals are predominantly metal complexes with an organic chelator for metal-essential 
agents or a chelator-biomolecule conjugate for target-specific radiopharmaceuticals. In gen-
eral, a target-specific radiopharmaceutical can be divided into four parts: targeting biomole-
cule (BM), pharmacokinetic modifying (PKM) linker, bifunctional coupling or chelating agent 
(BFC) and radionuclide.
7. Bifunctional chelating agents (BFC)
Chelators used for labeling with PET radionuclides are usually dominated by polydentate 
chelators like 1,4,7-triazacyclononane-triacetic acid (NOTA), 1,4,7,10-tetraazacyclododec-
ane-tetraacetic acid (DOTA), diethylenetriaminepentaacetic acid (DTPA), DTPA-monoamide 
and 4-(4,7-bis(2-(tert-butoxy)-2-oxoethyl)-1,4,7-triazacyclononan-1-yl)-5-(tert-butoxy)-
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5-oxopentanoic acid (NODA-GA (tBu)3) etc. These chelators are also called as “bifunctional chelating agents” as they possess a metal binding moiety as well as a chemically reactive 
functional group. The radionuclide of interest can bind to the metal binding moiety and the 
chemically reactive functional group provides the requisite chemistry for covalent attach-
ment to the targeting vector/carrier of interest like proteins [38], peptides [39] or nanopar-
ticles. BFC is covalently attached to the targeting molecule and strongly coordinates the 
radio-metal. The design of BFC depends upon number of fundamental criteria. Foremost 
seems the metal complex stability followed by other coordination chemistry criteria such 
as charge, chelator cavity size compatibility with the ionic radius of the radionuclide, che-
late denticity and availability of donor binding groups of appropriate chemical character. 
Two additional properties are also critical to consider: the rate at which the metal complex 
forms and the rate of dissociation. All of these criteria are interrelated. Cavity size must 
accommodate the ionic radius of the radionuclide such that all of required donor groups 
can be properly aligned for optimal binding to the metal ion in such a way to adequately 
encapsulate the ion thereby providing high stability and limiting dissociation. The suitable 
radio-metals are diverse in their properties and coordination chemistry, so, unfortunately 
there is no bifunctional chelating agent suitable for all radionuclides. The selection of BFC 
depends upon the oxidation state of the radio-metal that makes it imperative to understand 
the coordination chemistry of chelators with any given radionuclide to be labeled. Any BFC 
that forms a thermodynamically stable radio-metal chelate with high kinetic inertness is 
considered as an ideal BFC.
8. Chelating groups/techniques
There are several conjugation groups that can be used for the attachment of a BFC to the biomole-
cule like anhydride, isothiocyanate, bromoacetamide, iodoacetamide, N-hydroxysuccinimide 
(NHS) ester and maleimide. All of these conjugation groups are electrophiles, which require 
a nucleophile functionality in the biomolecule but in some cases, the biomolecule of interest 
contains groups like carboxylic acid only which are electrophilic in nature. In these cases, a 
nucleophile like ethylenediamine, is used to convert the electrophilic group into a nucleo-
philic group. These reactive groups, can serve as “linkers” for conjugation of a BFC. Selection 
of conjugation group depends largely on the “linker” in biomolecules. Very often the “linker” 
is a primary amine or a thiol group. The functional groups reactive toward primary amines 
include DTPA dianhydride, NHS-activated esters and isothiocyanates while maleimide is 
very reactive to thiols.
DTPA anhydride – DTPA dianhydride is commercially available and reacts readily with 
primary amines to form the DTPA-biomolecule conjugate in both aqueous and non-aque-
ous media [40, 41]. For small biomolecules, the cross-linking may result in the improved 
receptor binding kinetics and proves to be beneficial because simultaneous binding of two 
biomolecules on adjacent receptor sites will result in a slow dissociation of the receptor 
ligand. Asymmetric anhydrides of DTPA and DOTA have also been used to prepare their 
bio conjugates [42–44].
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NHS ester – The NHS esters have intermediate reactivity toward amines and are highly selec-
tive for aliphatic amines at an optimum pH of 8.0–9.0 in aqueous systems. Molecules con-
taining a carboxylic group can be converted into its NHS ester, making NHS-activated ester 
groups among the most powerful and the most commonly used conjugation groups for large 
(antibodies) and small biomolecules [45, 46].
Isothiocyanates – Isothiocyanates are also reactive to amine groups, and form thiourea bonds 
with primary amines from proteins or small biomolecules. They show intermediate reactivity 
toward amines at pH 9.0–9.5 in aqueous solutions and are more stable in water than NHS esters.
Aromatic isothiocyanates are often used to conjugate biomolecules onto DTPA and DOTA 
analogs [45, 46].
Maleimide – Maleimide reacts with a thiol group at a pH of 7.0 and leads to the formation 
of a thioether bond [47]. Maleimides can hydrolyze at higher pH (>8.0) to form non-reactive 
maleimic acids. The only limitation of using maleimide as a conjugation group is that not 
many biomolecules contain thiol groups thereby limiting the use of maleimide as a chelator.
Radiolabeling of DTPA and DOTA-biomolecule conjugates – DTPA analogs have a major 
advantage of being used as BFCs as they can be radiolabeled with high labeling efficiency 
even under mild conditions, but the kinetic instability of these metal chelates results in dis-
sociation of the radio-metal from the chelate.
DOTA analogs can be used as BFCs because if the kinetic inertness of their radio-metal che-
lates. However, the radiolabeling of DOTA chelates depends upon various factors like chelate 
concentration, pH, reaction temperature and incubation time, buffer concentration and pres-
ence of metal ions such as Zn (II) and Fe (III) [48–51]. In spite of the high solution stability of 
their radio-metal chelates, slow radiolabeling kinetics remains a major obstacle for the wide 
use of DOTA analogs as BFCs in target-specific radiopharmaceuticals. Coordination chemis-
try plays an imperative role in designing BFCs, radiolabeling, solution stability, modification 
of pharmacokinetics and formulation development.
9. Characterization and purification techniques
Certain mass spectroscopic techniques are utilized to determine the yields of bio-conjugation 
reactions. Liquid chromatography-mass spectrometry (LC–MS) technique is used for the 
characterization of dendrimers with mass below 3000 Da. Electrospray ionization-mass spec-
trometry (ESI-MS) is used for dendrimers which are able to form stable multiple charged spe-
cies. Matrix assisted laser desorption ionization: time of flight mass spectrometry technique 
(MALDI-tof) is used to characterize the chelate dendrimer conjugates with high molecular 
weight. These mass spectrometric techniques are used to analyze and compare the mass 
spectra of unmodified dendrimers and dendrimer-chelate conjugates in order to confirm the 
degree of conjugation. The average number of chelate molecules conjugated at the surface of 
dendrimer molecule is calculated using the formula:
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  Number of DOTA molecules conjugated =  [ (Increase in molecular weight relative to
 unmodified dendrimer) ÷  (Molecular weight of BFC) ] . (1)
Conjugation of BFCs with dendrimer can also be confirmed by Fourier transform-infrared 
spectroscopy (FT-IR). Chromatography techniques like size exclusion chromatography (SEC) 
helps in the purification and separation of dendrimer-chelate conjugates from free BFC’s 
according to their sizes.
10. Dendrimer-chelate cytotoxicity
“Cationic” dendrimers (e.g., amine terminated PAMAM dendrimers) are generally hemo-
lytic and cytotoxic [52]. The toxicity of dendrimers depends upon the generation number and 
increases with the increasing number of surface groups. Anionic dendrimers that bear carbox-
ylate surface groups are not cytotoxic even at a broad concentration range [53]. Amine termi-
nated PAMAM dendrimers are believed to have been showing more cytotoxicity because of 
the interaction between positively charged dendrimers and the negatively charged cell mem-
branes [54]. Thus, the cytotoxicity of these cationic dendrimers can be decreased by either 
shielding or decreasing the positive charge on their surface. Thus, the positively charged 
groups are usually capped with neutral molecules [55, 56]. Similarly, the surface amino 
groups/carboxylate groups of dendrimers are modified with BFCs resulting in a significant 
decrease in the number of positive charges on their surface. The toxicity of dendrimers on 
cells is concentration, time and generation dependent. Previous studies have demonstrated 
that the dendrimers with surface modifications are less toxic and more biocompatible when 
compared with the unmodified dendrimers [52, 54].
11. Radiolabeling of dendrimer-chelate conjugates
The radiolabeling of the purified and characterized dendrimer-chelate conjugates depends 
upon various factors and needs to be standardized. The ability of these bifunctional chelators 
to coordinate with a variety of metals makes them more sensitive to metallic impurities and 
contaminants en route the reaction process. Also, considerable attention has to be given for 
optimizing the reaction conditions so as to achieve best results for all conjugation and radio-
labeling experiments [57]. Factors like buffer pH, buffer volume, concentration of conjugate 
and incubation time has to be optimized in order to achieve best radiolabeling efficiency. The 
lead for setting up the range of test conditions for optimizing the radiolabeling of dendrimers 
with different radio-metals was taken from the previous studies [58].
12. 68Ga containing dendrimers for PET imaging
More than 80.0% of the radiopharmaceuticals used in nuclear medicine imaging are 99mTc based 
tracers. Among, several PET radionuclides, there has been a renewed interest in 68Ga for many 
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reasons. 68Ga is well suited for use as a radiolabel for PET because of its comparatively shorter 
half-life of 68 min. The emission of two divergent photons per decay allows the construction 
of three-dimensional images. Also, the advances in generator technology for 68Ga production, 
favorable chemistry of 68Ga for radio-complexation have paved the way for emerging applica-
tions of 68Ga radiopharmaceuticals [59]. The most stable oxidation state of gallium in aqueous 
solution is +3 and its coordination number is 6. The coordination chemistry of Ga3+ is very sim-
ilar to high spin Fe3+ ion. Both the ions have oxidation state of +3 and have almost same ionic 
radii (62 pm for Ga3+ and 65 pm for Fe3+). Ga(III) can undergo ligand exchange with protein 
transferrin when injected into the biological system. Transferrin contains two iron binding 
sites with high affinity for this metal ion. At physiological conditions, the human transferrin 
has a high binding affinity for Ga3+ given by log KST = 20.3 [60]. Thus, radiolabeling of 68Ga is 
best achieved by using bifunctional chelators which can strongly chelate the gallium ion and 
are covalently bound to targeting vectors [61, 62]. The most widely used bifunctional chelator 
for 68Ga radionuclide labeling is DOTA [63]. Ga(DOTA) complex is stable enough to be used in 
clinical practice. These macrocyclic chelators display high conformational and size selectivity 
toward metal ions. This category of chelators can encapsulate the metal ions with high effi-
ciency keeping it away from the competing species like blood transferrin [64].
The pH of buffer plays an important role in radiolabeling procedures especially with 68Ga. In 
aqueous solution, free hydrated gallium, that is, [Ga(H
2
O)
6
]3+ is stable under acidic conditions 
(pH < 3). At slightly higher pH, the aqueous solution chemistry is determined by the hydro-
lysis of the aqua ion leading to the formation of insoluble trihydroxide, that is, Ga(OH)3. At physiological pH, the solubility of gallium is high due to the exclusive formation of [Ga(OH)4−] 
ions [61]. Formation of Ga(OH)3 due to the hydrolysis can be avoided by using stabilizing weak ligands like acetate, citrate or HEPES as conjugating as well as radiolabeling buffers. 
For use as a radiopharmaceutical, a gallium compound must be either thermodynamically 
stable toward hydrolysis at physiological pH or be kinetically stable in the time frame of an 
imaging procedure. The reaction kinetics for the incorporation of Ga3+ is inversely related to 
pH [65]. The complexation of Ga3+ by DOTA shows slow kinetics because of its cavity size 
and eight donor atoms. Therefore, the radiolabeling procedures were carried at an elevated 
temperature of 90–100°C.
13. Quality control
ITLC – The radiolabeling efficiency is estimated chromatographically using ITLC-silica 
gel strips as the stationary phase and solvents such as ammonium acetate: methanol as 
mobile phase. The radiolabeled preparation is spotted at the origin of ITLC strips, dried 
and introduced into the solvent chamber containing mobile solvent. The mobile solvent is 
allowed to reach the top of the ITLC strip; the strip is removed, dried in air, cut into two 
halves and measured for its radioactivity in order to calculate its radiolabeling efficiency. 
The retention factor (R
f
) can also be calculated, the strips are marked from origin and 
divided into 10 equal sections each of 1.0 cm. The strips are cut, put into the test tubes and 
counts can be recorded in sodium iodide (NaI) well counter. The observed counts from 
each segment can be plotted as a linear graph and the R
f
 value for radiolabeled dendrimers 
can be evaluated.
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In vitro stability assay – The in vitro stability of the radiolabeled formulation can be deter-
mined by radio-chromatography using ITLC. The radiolabeling efficiency of the formulation 
is calculated at various time intervals. This assay depicts the pattern of degradation of radio-
labeled formulation as a function of time.
In vitro serum stability assay – The stability of radiolabeled dendrimers in systemic circula-
tion is usually evaluated by performing serum stability assay. The radiolabeled formulation 
is measured for any degree of degradation, if any due to enzymatic or other factors present 
in the blood/serum.
Lipophilicity assay – Affinity of radiolabeled formulation toward the organic phase (octanol) 
and aqueous phase, phosphate buffered saline (PBS) can be determined by calculating the 
organic/aqueous partition coefficient. Log P value is considered as the measure of lipophilic-
ity and can be calculated by using the formula:
  Log P = log  [Counts in organic phase  (octanol)  / Counts in aqueous phase  (PBS) ] (2)
14. Biodistribution and dosimetry studies
It is important to perform biodistribution and dosimetry studies with any new radiopharmaceuti-
cal to study the dose absorbed by various “critical organs” and also to study the pharmacokinetics 
of these newer tracers [66]. The documentation of pharmacokinetics and dosimetry data and sub-
mission of the same to the ‘regulatory authorities’ provide a robust evidence for seeking permission 
to carry out first ‘human studies’ and thus, has a translational relevance. Whenever new or experi-
mental radiopharmaceuticals are administered to patients, it becomes mandatory to get information 
on the patient’s radiation exposure by performing a dosimetry study. The procedure used to assess 
the organ’s absorbed doses has been summarized in MIRD pamphlet number 21 [67] and includes 
two major steps. Firstly, the quantification of the time integrated activity for each tissue localizing 
the radiopharmaceutical and secondly, determination of the S values, that is, the absorbed dose 
to target tissues per decay, in each source tissue were carried out. The S values for a radionuclide 
as required for the internal dosimetry must be based upon the internationally accepted reference 
anatomic phantoms as defined by the International Commission on Radiological Protection [68]. 
Further, the effective dose can be calculated by using the tissue weighing factors and the absorbed 
dose values to the organs. The critical organs of interest in humans for the use of a new radiophar-
maceutical clinically are generally evaluated in preclinical studies in rodents and other mammalian 
species. However, estimates derived from the animal studies are usually considered sufficient for 
the purpose of grant of regulatory permissions for human trials [69].
15. Molecular imaging with radiolabeled dendrimers
Dendrimers can be used to target the tumor vasculature by modifying their surface 
through covalent conjugation. Such a modification increases the targeting potential of 
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dendrimers toward cancer cells [70]. A combination of imaging modalities and several 
biocompatible and biodegradable dendrimers over the decade has been used to develop 
bio-imaging probes that have prolonged plasma half-lives, enhanced stability, reduced 
toxicity and improved target specificity. However, the application of dendrimers in 
nuclear medicine and radiochemistry is still at its infancy. With the escalating knowledge 
of science and research in the field of oncology, the development of new drug delivery 
systems has attained great heights. It is believed that rapid technological and scientific 
progresses in the development of bio-imaging dendrimers and their role as drug delivery 
agents will provide new research opportunities for use of dendrimers in the preclinical 
and clinical development of new therapies. Due to the 3-dimensional structure and pres-
ence of numerous functional groups on the surface, dendrimers have generated huge 
interest and attention as drug delivery systems. They provide a platform for attaching 
drugs or genes and further releasing them through several mechanisms which include 
either in vivo degradation of drug dendrimer covalent bonding due to the presence of 
certain enzymes or drug release due to changes in physical environment such as pH and 
temperature.
16. Conclusion
The high loading capacity of dendrimers enables them to deliver chemotherapeutic agents 
as well. The dendrimer-drug complexes designed for either targeted or non-targeted drug 
delivery successfully penetrate through the leaky vasculature of tumor and accumulate in the 
cancer tissue. However, the added advantage of using dendrimer-drug complexes specifi-
cally designed for targeted delivery is that they bind to specific receptors overexpressed on 
the surface of cancer cells, thereby, increasing their residence time over the cell surface. Thus, 
the development of dendrimer complexes that incorporates the targeting ligands, anticancer 
drugs and PET/β emitting radionuclides may provide the way for combinational anticancer 
therapies along with the in vivo imaging of the targeted tumor.
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